Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer

NCT03433313 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

807

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: EG12014
DRUG: Herceptin

Sponsor

EirGenix, Inc.